Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17103890 | 0.81 | MAOA (0.30) | — | |
| SCHEMBL30564264 | 0.70 | KDM1A (0.30) | — | |
| SCHEMBL16964130 | 0.70 | CHRNB4 (0.30) | CHRNB4CHRNA3 | |
| SCHEMBL30834466 | 0.69 | TRPA1 (0.44) | — | |
| SCHEMBL31359422 | 0.67 | — | — | |
| SCHEMBL2972520 | 0.67 | — | — | |
| SCHEMBL20571518 | 0.67 | KDM1A (0.30) | — | |
| SCHEMBL17103960 | 0.67 | — | — | |
| SCHEMBL29733099 | 0.67 | NOS3 (0.30) | — | |
| SCHEMBL9572969 | 0.65 | ADRA2A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624035-B2 | Compounds for targeted protein degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-20260070904-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2026-03-12 | — | — | US | disclosed |
| CN-107108583-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070904-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BRD9, BRWD1, BRD1 | CHRNB4 3909/4885CHRNA3 3896/4885 |
| US-12624035-B2 | Compounds for targeted protein degradation | BRD9, BRD1, BRD3 | CHRNB4 3584/4885CHRNA3 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.